Durable Discontinuation of Systemic Therapy in Patients Affected by Chronic Graft-versus-Host Disease

Scientists evaluated the factors associated with durable systemic therapy (ST) discontinuation, defined as cessation of all ST for ≥12 months, using data from two prospectively followed cohorts from the chronic graft-versus-host disease Consortium.